The Medtronic Newsroom is designed to assist media in finding news and information about our company.
Medtronic, founded in a Minneapolis garage in 1949 by Earl Bakken and his brother-in-law, Palmer Hermundslie, is the world’s leading maker of medical devices.
Our Mission has not changed since Earl Bakken wrote it in 1960: To contribute to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health and extend life.
More than 9 million lives are enhanced every year by a Medtronic product or therapy; that’s one every three seconds.
Medtronic is headquartered in Minneapolis, MN and operates in more than 140 countries. The company employs 46,000 people, including 5,800 scientists and engineers, pursuing research and innovation that has led to more than 28,000 patents.
|12/05/13||Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2014|
|MINNEAPOLIS - December 5, 2013 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.28 per share of the Company's common stock. The dividend is payable on January 24, 2014, to shareholders of record at the close of business on January 3, 2014. About MedtronicMedtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the w... |
|12/05/13||First U.S. Implants of New Medtronic Deep Brain Stimulation System Advance Ground-Breaking Research Into Brain Activity While Therapy Is Delivered |
|Activa® PC+S Deep Brain Stimulation System Enables Research Toward Personalized Treatment of Neurological and Psychological Diseases MINNEAPOLIS - December 5, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the first U.S. implants of a novel deep brain stimulation (DBS) system in research that may one day transform the treatment of devastating neurological and psychological disorders, such as Parkinson's disease, essential tremor, dystonia, and treatment-resistant obsessive-compulsive disord... |
|12/05/13||Medtronic Announces CE Mark and TGA Listing for the Symplicity Spyral(TM) Multi-Electrode Catheter and Symplicity G3(TM) Generator|
|Multi-Electrode System Built Upon Clinical Success and Strong Safety Profile of Single-Electrode Symplicity(TM) Renal Denervation System MINNEAPOLIS -- December 5, 2013 -- Medtronic, Inc. (NYSE: MDT), announced today CE Mark (Conformité Européenne) in Europe and Therapeutic Goods Administration (TGA) listing in Australia for its highly flexible 4 Fr multi-electrode Symplicity Spyral(TM) catheter and Symplicity G3(TM) radio frequency (RF) generator. This new system is designed to significantly ... |
|Receive E-mail Alerts |
|Sign up to receive e-mail alerts whenever Medtronic posts new information to the site. Just enter your e-mail address and click Submit.|